Genome Aberrations in Canine Mammary Carcinomas and Their Detection in Cell-Free Plasma DNA

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Beck, Julia ^a   Hennecke, Silvia ^b   Bornemann Kolatzki, Kirsten ^a   Urnovitz, Howard B ^a   Neumann, Stephan ^b   Ströbel, Philipp ^c   Kaup, Franz Josef ^d   Brenig, Bertram ^b   Schütz, Ekkehard ^a,b  

^a Chronix Biomedical   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d GERMAN PRIMATE CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENOMIC DNA;

ANEUPLOIDY; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST SURGERY; CANCER CLASSIFICATION; CANCER STAGING; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DETERMINATION; DOG; DROPLET DIGITAL POLYMERASE CHAIN REACTION; FEMALE; GENE DELETION; GENE FUSION; GENETIC POLYMORPHISM; GENETIC PROCEDURES; GENETIC VARIABILITY; GENOME ANALYSIS; HISTOPATHOLOGY; MASSIVE PARALLEL SEQUENCING; NONHUMAN; NUCLEIC ACID ANALYSIS; ONCOGENE; ONCOGENE C MYC; ONCOGENE KIT; PFDN5 GENE; STRUCTURAL CHROMOSOME ABERRATION; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; CELL-FREE SYSTEM; CHROMOSOME ABERRATIONS; DNA; DNA COPY NUMBER VARIATIONS; DNA PRIMERS; DOG DISEASES; DOGS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA;

EID: 84884755580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075485     Document Type: Article

References (92)

1. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR, (1968) Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 40: 307-318.
2. Sleeckx N, de Rooster H, Veldhuis Kroeze EJ, Van Ginneken C, Van Brantegem L, (2011) Canine mammary tumours, an overview. Reprod Domest Anim 46: 1112-1131.
3. Vascellari M, Baioni E, Ru G, Carminato A, Mutinelli F, (2009) Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet Res 5: 39.
4. Dobson JM, Samuel S, Milstein H, Rogers K, Wood JL, (2002) Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 43: 240-246.
5. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, et al. (2008) Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med 22: 976-984.
6. Paoloni M, Khanna C, (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156.
7. Rowell JL, McCarthy DO, Alvarez CE, (2011) Dog models of naturally occurring cancer. Trends Mol Med 17: 380-388.
8. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, et al. (2005) Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438: 803-819.
9. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, et al. (2006) The dog as a cancer model. Nat Biotechnol 24: 1065-1066.
10. Queiroga FL, Raposo T, Carvalho MI, Prada J, Pires I, (2011) Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo 25: 455-465.
11. Sassi F, Benazzi C, Castellani G, Sarli G, (2010) Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Vet Res 6: 5.
12. Gama A, Alves A, Schmitt F, (2008) Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 453: 123-132.
13. Tsuda H, (2009) Gene and chromosomal alterations in sporadic breast cancer: correlation with histopathological features and implications for genesis and progression. Breast Cancer 16: 186-201.
14. Rutteman GR, Misdorp W, Blankenstein MA, van den Brom WE, (1988) Oestrogen (ER) and progestin receptors (PR) in mammary tissue of the female dog: different receptor profile in non-malignant and malignant states. Br J Cancer 58: 594-599.
15. Nieto A, Pena L, Perez-Alenza MD, Sanchez MA, Flores JM, et al. (2000) Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol 37: 239-247.
16. Morris JS, Dobson JM, Bostock DE, (1993) Use of tamoxifen in the control of canine mammary neoplasia. Vet Rec 133: 539-542.
17. Simon D, Schoenrock D, Baumgartner W, Nolte I, (2006) Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 20: 1184-1190.
18. Hellmen E (2005) Complex mammary tumours in the female dog: a review. J Dairy Res 72 Spec No: 90-97.
19. Strandberg JD, Goodman DG, (1974) Animal model of human disease: canine mammary neoplasia. Am J Pathol 75: 225-228.
20. Negrini S, Gorgoulis VG, Halazonetis TD, (2010) Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220-228.
21. Angstadt AY, Motsinger-Reif A, Thomas R, Kisseberth WC, Guillermo Couto C, et al. (2011) Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart. Genes Chromosomes Cancer 50: 859-874.
22. Maeda J, Yurkon CR, Fujisawa H, Kaneko M, Genet SC, et al. (2012) Genomic instability and telomere fusion of canine osteosarcoma cells. PLoS One 7: e43355.
23. Tang J, Le S, Sun L, Yan X, Zhang M, et al. (2010) Copy number abnormalities in sporadic canine colorectal cancers. Genome Res 20: 341-350.
24. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
25. Muller MH, Reimann-Berg N, Bullerdiek J, Murua Escobar H, (2012) Genetic characterization of dogs via chromosomal analysis and array-based comparative genomic hybridization (aCGH). Tierarztl Prax Ausg K Kleintiere Heimtiere 40: 55-58.
26. Thomas R, Duke SE, Bloom SK, Breen TE, Young AC, et al. (2007) A cytogenetically characterized, genome-anchored 10-Mb BAC set and CGH array for the domestic dog. J Hered 98: 474-484.
27. Nicholas TJ, Baker C, Eichler EE, Akey JM, (2011) A high-resolution integrated map of copy number polymorphisms within and between breeds of the modern domesticated dog. BMC Genomics 12: 414.
28. Schweiger MR, Kerick M, Timmermann B, Isau M, (2011) The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. Cancer Metastasis Rev 30: 199-210.
29. Mandel P, Métais P, (1948) Les acides nucléiques du plasma sanguin chez l'homme. C R Acad Sci Paris 142: 241-243.
30. Schwarzenbach H, Hoon DS, Pantel K, (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-437.
31. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, et al. (1994) Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 3: 67-71.
32. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, et al. (1994) Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 86: 774-779.
33. Beck J, Urnovitz HB, Mitchell WM, Schutz E, (2010) Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 8: 335-342.
34. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, et al. (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2: 20ra14.
35. McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, et al. (2010) Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 49: 1062-1069.
36. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, et al. (2012) Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing. Clin Chem.
37. Shaw JA, Page K, Blighe K, Hava N, Guttery D, et al. (2012) Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 22: 220-231.
38. Allred DC, Harvey JM, Berardo M, Clark GM, (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168.
39. Miller SA, Dykes DD, Polesky HF, (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
40. McKernan KJ, Peckham HE, Costa GL, McLaughlin SF, Fu Y, et al. (2009) Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res 19: 1527-1541.
41. Xie C, Tammi MT, (2009) CNV-seq, a new method to detect copy number variation using high-throughput sequencing. BMC Bioinformatics 10: 80.
42. Parzen E, (1962) On the estimation of a probability density and the mode. The Annals of Mathematical Statistics 33: 1065-1076.
43. Rosenblatt M, (1956) Remarks on Some Nonparametric Estimates of a Density Function. The Annals of Mathematical Statistics 37: 832-837.
44. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. JR Statist Soc B 57: 289-300.
45. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, et al. (2009) Circos: an information aesthetic for comparative genomics. Genome Res 19: 1639-1645.
46. Cancer Genome Atlas N, (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
47. Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, et al. (2005) High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 7: R1186-1198.
48. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, et al. (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085-2094.
49. Zeitouni B, Boeva V, Janoueix-Lerosey I, Loeillet S, Legoix-ne P, et al. (2010) SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. Bioinformatics 26: 1895-1896.
50. Pinheiro LB, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, et al. (2012) Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. Anal Chem 84: 1003-1011.
51. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486: 353-360.
52. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, et al. (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149: 979-993.
53. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395-399.
54. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, et al. (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005-1010.
55. Grzmil M, Kaulfuss S, Thelen P, Hemmerlein B, Schweyer S, et al. (2006) Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells. J Pathol 208: 340-349.
56. Fujioka Y, Taira T, Maeda Y, Tanaka S, Nishihara H, et al. (2001) MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer. J Biol Chem 276: 45137-45144.
57. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
58. Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR, (2008) Defining 'chromosomal instability'. Trends Genet 24: 64-69.
59. Martin JW, Squire JA, Zielenska M, (2012) The genetics of osteosarcoma. Sarcoma 2012: 627254.
60. Hellmen E, Lindgren A, Linell F, Matsson P, Nilsson A, (1988) Comparison of histology and clinical variables to DNA ploidy in canine mammary tumors. Vet Pathol 25: 219-226.
61. Rutteman GR, Cornelisse CJ, Dijkshoorn NJ, Poortman J, Misdorp W, (1988) Flow cytometric analysis of DNA ploidy in canine mammary tumors. Cancer Res 48: 3411-3417.
62. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, et al. (2006) Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 16: 1465-1479.
63. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR, (2010) Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol 4: 255-266.
64. Liu P, Carvalho CM, Hastings PJ, Lupski JR, (2012) Mechanisms for recurrent and complex human genomic rearrangements. Curr Opin Genet Dev 22: 211-220.
65. Maher CA, Wilson RK, (2012) Chromothripsis and human disease: piecing together the shattering process. Cell 148: 29-32.
66. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27-40.
67. Loeb LA, Loeb KR, Anderson JP, (2003) Multiple mutations and cancer. Proc Natl Acad Sci U S A 100: 776-781.
68. Fabarius A, Hehlmann R, Duesberg PH, (2003) Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet 143: 59-72.
69. Boerkamp K, Rutteman G, Kik M, Kirpensteijn J, Schulze C, et al. (2012) Nuclear DNA-Content in Mesenchymal Lesions in Dogs: Its Value as Marker of Malignancy and Extent of Genomic Instability. Cancers 4: 1300-1317.
70. Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, et al. (2010) Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2: 38ra47.
71. Dunn KA, Thomas R, Binns MM, Breen M, (2000) Comparative genomic hybridization (CGH) in dogs-application to the study of a canine glial tumour cell line. Vet J 160: 77-82.
72. Thomas R, Smith KC, Ostrander EA, Galibert F, Breen M, (2003) Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. Br J Cancer 89: 1530-1537.
73. Thomas R, Bridge W, Benke K, Breen M, (2003) Isolation and chromosomal assignment of canine genomic BAC clones representing 25 cancer-related genes. Cytogenet Genome Res 102: 249-253.
74. Drabsch Y, Robert RG, Gonda TJ, (2010) MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res 12: R55.
75. Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, et al. (2000) MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res 60: 5323-5328.
76. Thomas R, Wang HJ, Tsai PC, Langford CF, Fosmire SP, et al. (2009) Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Res 17: 365-377.
77. Reimann-Berg N, Murua Escobar H, Nolte I, (2012) Relevance of chromosome 13 aberrations in canine tumours. Tierarztl Prax Ausg K Kleintiere Heimtiere 40: 267-270.
78. Pierotti MA, Sozzi G, Croce CM (2003) Mechanisms of oncogene activation; Kufe DW, Pollock RE, Weichselbaum RR, editors: BC Decker Available: http://www.ncbi.nlm.nih.gov/books/NBK12538/.Accessed 2013 May.
79. Klopfleisch R, von Euler H, Sarli G, Pinho SS, Gartner F, et al. (2011) Molecular carcinogenesis of canine mammary tumors: news from an old disease. Vet Pathol 48: 98-116.
80. Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, et al. (2009) Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 10: 135.
81. Ahern TE, Bird RC, Bird AE, Wolfe LG, (1996) Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. Am J Vet Res 57: 693-696.
82. Martin de las Mulas J, Ordas J, Millan Y, Fernandez-Soria V, Ramon y Cajal S, (2003) Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Res Treat 80: 363-367.
83. Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM, (2004) Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 122: 110-119.
84. Owens MA, Horten BC, Da Silva MM, (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5: 63-69.
85. Aguirre-Hernandez J, Milne BS, Queen C, O'Brien PC, Hoather T, et al. (2009) Disruption of chromosome 11 in canine fibrosarcomas highlights an unusual variability of CDKN2B in dogs. BMC Vet Res 5: 27.
86. Hagio Y, Kimura Y, Taira T, Fujioka Y, Iguchi-Ariga SM, et al. (2006) Distinct localizations and repression activities of MM-1 isoforms toward c-Myc. J Cell Biochem 97: 145-155.
87. Rao NA, van Wolferen ME, Gracanin A, Bhatti SF, Krol M, et al. (2009) Gene expression profiles of progestin-induced canine mammary hyperplasia and spontaneous mammary tumors. J Physiol Pharmacol 60Suppl 1: 73-84.
88. Graham JC, O'Keefe DA, Gelberg HB, (1999) Immunohistochemical assay for detecting estrogen receptors in canine mammary tumors. Am J Vet Res 60: 627-630.
89. de Las Mulas JM, Millan Y, Dios R, (2005) A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol 42: 200-212.
90. Lo YM, Lun FM, Chan KC, Tsui NB, Chong KC, et al. (2007) Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci U S A 104: 13116-13121.
91. Hedan B, Thomas R, Motsinger-Reif A, Abadie J, Andre C, et al. (2011) Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior. BMC Cancer 11: 201.
92. Mitelman F, Johansson B, Mertens FE (2012) Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. In: Mitelman F, Johansson B, Mertens F, editors.